Telavancin for refractory methicillin-resistant<i>Staphylococcus aureus</i>bacteremia and infective endocarditis

Ruggero, Michael; Peaper, David R.; Topal, Jeffrey

doi:10.3109/00365548.2014.995696

Cited by 29 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the ATTAIN trial, those patients with bacteraemic hospital‐acquired pneumonia were compared with telavancin demonstrating a higher cure rate numerically, although further exploration is warranted . A case series of 14 patients with persistent MRSA bacteraemia failing vancomycin or daptomycin were treated with telavancin resulting in a 57% (8/14) success rate with 62% (9/14) of patients experiencing culture clearance within 48 hours . Another case series with eight patients undergoing haemodialysis with persistent MRSA bacteraemia failing vancomycin or daptomycin were switched to telavancin 10 mg/kg thrice weekly or every other day.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Vancomycinand daptomycin-sparing regimens for persistent MRSA bacteraemia within 48 hours 75. Another case series with eight patients undergoing haemodialysis with persistent MRSA bacteraemia failing vancomycin or daptomycin were switched to telavancin 10 mg/kg thrice weekly or every other day.…”

mentioning

confidence: 99%

Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Madrigal et al and Miro et al reported that TLV monotherapy (at humanized therapeutic doses) was sufficient to significantly reduce bacterial counts in vegetations in a methicillin-resistant S. aureus rabbit model of aortic valve endocarditis, leading to sterilization of vegetations in some animals (17,18). Clinical reports have also illustrated the successful use of TLV in cases of infective endocarditis caused by Corynebacterium striatum and S. aureus refractory to VAN or DAP (30)(31)(32)(33)(34). However, in vivo and clinical data on the use of TLV against deep-seated or endovascular enterococcal infections are lacking.…”

Section: Discussionmentioning

confidence: 99%

“…Our results suggest that TLV alone or the combination of TLV plus AMP is worth additional studies to explore the feasibility of their use as possible alternative options for patients infected with E. faecalis strains when standard therapy is not effective, considering that the successful use of TLV in deep-seated bacterial infections is supported by only a few case reports of Corynebacterium striatum and S. aureus. Thus, further studies would be needed to establish a place in therapy of infective endocarditis (30)(31)(32)(33)(34). Moreover, due to the possibility of renal toxicity with the use of TLV (31), it is unclear if such toxicity would limit its clinical utility when longer courses of therapy are likely to be needed.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis

Tran

Tam

Murray

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We first assessed telavancin (TLV) pharmacokinetics in rats after a single subcutaneous dose of 35 mg/kg of body weight. The pharmacokinetic data were used to predict a TLV dose that simulates human exposure, and the efficacy of TLV was then evaluated using a TLV dose of 21 mg/kg every 12 h against Enterococcus faecalis OG1RF (TLV MIC of 0.06 g/ml) in a rat endocarditis model with an indwelling catheter. Therapy was given for 3 days with TLV, daptomycin (DAP), or ampicillin (AMP) monotherapy and with combinations of TLV plus AMP, AMP plus gentamicin (GEN), and AMP plus ceftriaxone (CRO); rats were sacrificed 24 h after the last dose. Antibiotics were given to simulate clinically relevant concentrations or as used in other studies. TLV treatment resulted in a significant decrease in bacterial burden (CFU per gram) in vegetations from 6.0 log 10 at time 0 to 3.1 log 10 after 3 days of therapy. Bacterial burdens in vegetations were also significantly lower in the TLVtreated rats than in the AMP (P ϭ 0.0009)-and AMP-plus-GEN (P ϭ 0.035)-treated rats but were not significantly different from that of the AMP-plus-CRO-treated rats. Bacterial burdens from vegetations in TLV monotherapy and TLV-plus-AMP-and-DAP groups were similar to each other (P Ն 0.05). Our data suggest that further study of TLV as a therapeutic alternative for deep-seated infections caused by vancomycinsusceptible E. faecalis is warranted.KEYWORDS telavancin, Enterococcus faecalis, therapy, rat endocarditis E nterococci are commensals of the normal human intestinal flora and a known cause of bacterial infective endocarditis (IE). In multiple studies, enterococci have been identified as the third most frequent cause of endocarditis (1-3), with Enterococcus faecalis causing the majority of these infections. A trend toward increasing drug resistance among traditional anti-enterococcal antibiotics (i.e., penicillin, ampicillin [AMP], vancomycin [VAN], and aminoglycosides) poses significant challenges for the treatment of severe infections caused by enterococci, in particular Enterococcus faecium (4, 5). Although most E. faecalis organisms remain susceptible to penicillin and AMP, these agents are usually combined with aminoglycosides or ceftriaxone (CRO) to achieve a bactericidal effect and higher cure rates. Telavancin (TLV) is among the newer agents with in vitro activity against glycopeptide-susceptible E. faecalis. TLV has FDA approvals for complicated skin and skin structure infections (6, 7) and hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable (8). The mechanism of bacterial killing by TLV includes inhibition of bacterial cell wall synthesis by interfering

show abstract

“…8 Fourteen patients, 11 of whom had endocarditis, received salvage therapy with telavancin after a median duration of persistent bacteremia of 13 days. 9 All 10 with follow-up cultures had clearance of MRSA of the bloodstream a median of 1 day (range, 1-3 days) after the therapeutic switch, although only 8 patients survived. A phase 3, multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy in the treatment of patients with S aureus bacteremia and right-sided infective endocarditis is ongoing.…”

Section: Dalbavancinmentioning

confidence: 97%

Bacteremia due to Methicillin-Resistant Staphylococcus aureus

Holubar

Meng

Deresinski

2016

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Telavancin for refractory methicillin-resistantStaphylococcus aureusbacteremia and infective endocarditis

Cited by 29 publications

References 23 publications

Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia

Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia

Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis

Bacteremia due to Methicillin-Resistant Staphylococcus aureus

Contact Info

Product

Resources

About